Samsung Bioepis says its trastuzumab biosimilar as safe, effective as original
Sept 13, 2021
South Korean pharmaceutical company Samsung Bioepis said Monday its breast cancer treatment biosimilar Ontruzant is proven to be just as safe and effective as the original drug. The Korean drugmaker conducted a follow-up study lasing five years, tracking 367 patients with human epidermal growth factor receptor 2 positive breast cancer. The patients received several cycles of trastuzumab biosimilar Ontruzant or the reference medicine along with chemotherapy and surgery during the period. S